# Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors

> **NCT05213767** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 190 (estimated)

## Conditions studied

- Advanced Tumors

## Interventions

- **DRUG:** TQB2916 injection

## Key facts

- **NCT ID:** NCT05213767
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02
- **Primary completion:** 2023-05
- **Final completion:** 2023-07
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2022-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05213767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05213767, "Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05213767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*